Soochow University Nanohybrids Mitigate Glucocorticoid Bone Loss in Rats

Researchers from Soochow University, Zhejiang University, and Nanyang Technological University have developed a pathology-adapted peptide-oligonucleotide nanohybrid (PON) designed to counteract glucocorticoid-induced bone loss (GIBL) nature.comNature Communicationsnature.comOpen source ↗. Glucocorticoid exposure often triggers systematic osteopenia and osteonecrosis of the femoral head, presenting a clinical challenge due to the simultaneous deterioration of bone architecture and local microvasculature. As reported in Nature Communications, the targeted modular delivery platform was engineered to deliver microRNA-26a-5p directly into injured osseous environments.

Targeted Nanohybrid Architecture

The PON design incorporates several functional features, including molecular self-assembly, affinity for bone tissue, enzyme-triggered responsiveness, cell-penetrating capabilities, and endosomal-lysosomal escape mechanisms. Together, these characteristics overcome traditional systemic transport barriers associated with oligonucleotide therapeutics, shielding the cargo and improving localization within glucocorticoid-damaged microenvironments. Systemic distribution of native oligonucleotides typically suffers from rapid degradation and low target-tissue bioaccumulation, issues addressed by this integrated delivery system.

Molecular Pathways and In Vivo Efficacy

Mechanistically, the targeted delivery of miR-26a-5p suppressed glycogen synthase kinase-3 beta (GSK-3β) expression and promoted the stabilization of hypoxia-inducible factor 1-alpha (HIF-1α). This dual effect sustained osteogenesis-angiogenesis coupling while reducing cellular apoptosis under glucocorticoid exposure. In rat disease models, systemic administration of the nanohybrids protected against initial skeletal and vascular degradation and limited pathological progression in established conditions.